A STUDY OF ADJUVANT CONCURRENT CHEMO-RADIOTHERAPY WITH CAPECITABINE IN ADENOCARINOMA STOMACH

Abstract

Introduction: Adenocarcinoma stomach is one of the leading causes of cancer related mortality in the world. Surgery is an established modality in the management of stomach cancer. Although it is well known that some form of adjuvant therapy is indicated, both chemotherapy and concurrent chemoradiotherapy give equivalent results.

Methodology: Our study is a prospective observational study of the stomach cancer patients receiving adjuvant concurrent chemoradiotherapy with capecitabine. A total of 41 patients with stomach cancer undergoing gastric resection with a curative intent were evaluated.

Results: With a Median follow up of 13 months, the estimated disease free survival was 21.2 months. Of the 41 patients, only 4 developed metastasis and none of the patients recurred locally. The regimen was well tolerated.

Conclusion: Concurrent chemoradiotherapy with capecitabine is well tolerated in our population with minimal side effects and good local control rate. Intensification of chemotherapy might reduce the incidence of metastasis.